Stay updated on Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to include new details about a clinical trial for Nadunolimab in combination with chemotherapy for advanced Triple Negative Breast Cancer, including the study's interventional model and collaborators. Notably, extensive background information on Triple Negative Breast Cancer has been removed.SummaryDifference51%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 14, 2025.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 14, 2025, and version 2.14.2.SummaryDifference0.1%
- Check52 days agoChange DetectedThe study is now marked as 'Active, not recruiting' and has updated its number of locations from 24 to 23. Additionally, the study dates have been revised to reflect new timelines.SummaryDifference1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.